Faculty of Medicine and Dentistry researcher Peter Light and his colleagues
discovered that new resveratrol-based drugs they created that were used in the lab, helped regulate electrical activity in the heart by inhibiting irregular electrical currents, and by reducing the length of abnormal heart-rhythm episodes.
These new medications they created targeted multiple activities in the cell, whereas current medications for heart rhythm problems target just one or two specific areas.
The research team is now working on advancing their drug design with colleagues at the Centre for Drug Research and Development, and via TEC Edmonton. Light expects that clinical trials with the advanced drug design will start within the next three to five years.
"We are at the next stage of developing a new oral medication for atrial fibrillation that patients could take on a daily basis to prevent this condition from occurring.
We are improving the medication's solubility, absorption, how it is metabolized and how long it stays in the blood stream," Light said.
The study is published in British Journal of Pharmacology.
--ANI (Posted on 08-10-2013)